A detailed history of Israel Englander (Millennium Management LLC) transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 33,844 shares of FDMT stock, worth $282,597. This represents 0.0% of its overall portfolio holdings.

Number of Shares
33,844
Previous 11,444 195.74%
Holding current value
$282,597
Previous $364,000 95.05%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$20.93 - $30.01 $468,832 - $672,224
22,400 Added 195.74%
33,844 $710,000
Q1 2024

May 15, 2024

BUY
$17.03 - $35.87 $194,891 - $410,496
11,444 New
11,444 $364,000
Q2 2023

Aug 14, 2023

BUY
$15.16 - $23.26 $4.23 Million - $6.48 Million
278,701 New
278,701 $5.04 Million
Q4 2022

Feb 14, 2023

BUY
$6.85 - $25.46 $187,511 - $696,942
27,374 Added 10.52%
287,483 $6.39 Million
Q3 2022

Nov 14, 2022

SELL
$6.96 - $11.48 $99,660 - $164,382
-14,319 Reduced 5.22%
260,109 $2.09 Million
Q2 2022

Aug 15, 2022

BUY
$5.68 - $15.99 $1.12 Million - $3.16 Million
197,504 Added 256.75%
274,428 $1.92 Million
Q1 2022

May 16, 2022

BUY
$13.16 - $22.64 $1.01 Million - $1.74 Million
76,924 New
76,924 $1.16 Million
Q4 2021

Feb 14, 2022

SELL
$19.56 - $32.94 $3.04 Million - $5.11 Million
-155,258 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$22.73 - $36.04 $4.47 Million - $7.09 Million
-196,793 Reduced 55.9%
155,258 $4.19 Million
Q2 2021

Aug 16, 2021

BUY
$22.2 - $42.29 $397,424 - $757,075
17,902 Added 5.36%
352,051 $8.48 Million
Q1 2021

May 17, 2021

SELL
$35.94 - $52.67 $364,215 - $533,757
-10,134 Reduced 2.94%
334,149 $14.5 Million
Q4 2020

Feb 16, 2021

BUY
$38.43 - $47.36 $13.2 Million - $16.3 Million
344,283 New
344,283 $14.3 Million

Others Institutions Holding FDMT

About 4D Molecular Therapeutics, Inc.


  • Ticker FDMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,382,400
  • Market Cap $270M
  • Description
  • 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...
More about FDMT
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.